xenpozyme
sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - citas gremošanas trakta un metabolisma produkti, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.
migregon (2022.) tablete
tablete
amvuttra
alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - other nervous system drugs - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
silicium (2023.) cits, gels
cits, gels
skindrink (2023.) cits, gels
cits, gels
relaxium (2023.) cits, gels
cits, gels
sportus (2023.) cits, gels
cits, gels
kālija jodīda šķīdums 2000 μg/ml (2023.) šķidrums
šķidrums
cosmofer 50 mg/ml šķīdums infūzijām un injekcijām
pharmacosmos a/s, denmark - dzelzs (iii) hidroksīda dekstrāna kompleks - Šķīdums injekcijām/infūzijām - 50 mg/ml
idafer 20 mg/ml šķīdums injekcijām
farmalog eood, bulgaria - dzelzs - Šķīdums injekcijām - 20 mg/ml